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I 522 High dose-rate (HDR) endobronchial brachytherapy associated or not with previous Nd-YAG laser 
therapy for lung cancer: Results and complications 
of a prospective study 
H.A. Carvalho, S. Aisen, M.C. Chavantes, W.L. Pedreira Jr., T.Y. Takagaki, 
C.M.K. Haddad, W. Nadalin. Univ. of Srio fau/o, 90 Paula, Brazil 
Objective: To evaluate the effectiveness of HDR brachytherapy in curative 
treatment and palliation of symptoms due to endobronchial lung cancer. 
Methods: From Jan. 91 to Oct. 96, 46 patients with malignant airway 
disease were treated with HDR brachytherapy. Only 36 cases, with histo- 
logic diagnostic of lung carcinoma and a minimum follow-up of 6 months, 
were included in this study. The patients were treated according to 3 cate- 
gories: a) curative - 8 patients; b) palliative - 9 patients and c) recurrences 
after previous irradiation and/or surgery - 19 patients. The curative group 
received concomitant external irradiation (60 Gy as standard) and HDR 
brachytherapy. In the other two groups, external irradiation was used when 
indicated. Brachytherapy was delivered in three fractions of 7.5 Gy each, 
fortnightly or weekly, according to the association or not with concomitant 
external irradiation respectively. Dose was prescribed at 1 cm from the axis 
of the catheter, with variations until 0.5 cm when segmental bronchi were 
irradiated. Neodimium-YAG laser was used previously for desobstruction 
or hemostasis in 13 patients. 
Results: In the curative category, mean survival was 30.1 months, with 
3 patients alive at 6,42 and 60 months. Of the group treated in the palliative 
category, one patient was alive at 6 months and the mean survival was 4 
months. Patients treated for recurrent disease had a mean survival of 11.4 
months with 1 patient alive at 60 months (salvage surgery after a second 
recurrence). Statistical analysis demonstrated a significant difference in 
survival among the 3 groups (p = 0.01). Symptom relief with improvement 
of the performance status was obtained in 85.2% of the cases. Complete 
or partial airway desobstruction occurred in 83.3%. Severe complication 
rate was 5.5%, represented by 2 patients not submitted to laser therapy 
(1 esophageal-mediastinal fistulae and 1 fatal hemoptysis associated with 
persistent tumor). 
Conclusions: Our results indicate that HDR endobronchial brachyther- 
apy may be useful in thecurative treatment of well selected cases. Palliation 
of symptoms with improvement of the quality of life is obtained in the ma- 
jority of the patients. In this study, association with laser therapy did not 
increase the complication rate. 
El 523 Combined modality treatment using concurrent radiotherapy [RT] and pharmacologically guided 
carboplatin for non-small cell lung cancer [NSCLC] 
M. Millward, S. Porceddu, D. Ball, A. Dowling, A. Wirth, G. Ryan, M. Mac 
Manus. Peter MacCallum Cancer Institute, Melbourne, Australia 
Background: In a previous randomized trial we observed a 50% increase 
in median survival in patients [pts] with inoperable NSCLC when carbo- 
platin was given concurrently with RT [60 Gy in 30 fractions given over 6 
weeks] compared with the same RT given alone. In that study, the dose 
of carboplatin was calculated according to the body surface area, but the 
safety and efficacy of the drug may be improved by pharmacologically 
guided dosing based on its renal excretion. 
Patients and Methods: Patients were eligible if they had unresectable 
or incompletely resected NSCLC, good performance status [ECOG O-l], 
weight loss .Z lo%, no evidence of distant metastases and adequate 
haematology and biochemistry. RT was given to the primary site and 
regional lymph nodes to a total dose of 60 Gy in 30 fractions over 6 weeks. 
Two cycles of carboplatin were given as daily one hour infusions before 
RT in weeks 1 and 6. A plasma area under the free platinum concentration 
versus time curve [AUC] of 7 mg/ml.min/cycle was targeted this being 
the known maximal single agent exposure. The total dose of carboplatin 
required was determined using the Calverl or Chatelut formula. 
Results: Between 1 l/95 and 1 l/96 31 patients were enrolled. Patient 
characteristics: 77% male; median age 69 [range 46-781; stage: I- 1 pt, 
II-2 pts, lllA-13 pts, IIIB-11 pts, incomplete resection-3 pts, and 1 pt locally 
recurrent after surgery. Median dose of carboplatin per cycle was 840 
mg [range 435-1350 mg]. 25 pts [81%] completed treatment as planned. 
Reasons for failure to complete treatment: 2 deaths [myocardial infarction]; 
2 pts progressive disease; and 2 pts did not complete 2nd cycle carboplatin 
- 1 neutropenia, 1 oesophagitis. Neutropenia: grade 3 occurred in 4 pts 
[13%], and 1 pt developed grade 4 and died of pulmonary sepsis after 2 
cycles each of 850 mg. Grade 3 thrombccytopenia occurred in only 2 pts 
and 2 pts developed grade 3 oesophagitis. 
Conclusions: Radical chest irradiation can be combined with 2 cycles 
of pharmacologically guided full dose carboplatin with acceptable toxicity in 
pts with NSCLC. The higher doses and the widevariation in total carboplatin 
dose indicates that this dosing method is preferable to a fixed mg/m* 
dosing. 
I 524 Concurrent PaclitaxeVCisplatin (PC) with thoracic radiation TTR) in oatients with staae Ills/b non-small 
cell lung danker (NSCLC) - 
H. Wagner, S.J. Antonia, C.C. Williams, M. Alberts, D. Hubbell, 
L. Robinson, J. Hilstro, J.C. Ruckdeschel, G.L. Shaw. h’. Lee Moffitt 
Cancer Center, University of South Florida, Tampa FL 33612, USA 
Early concurrent use of chemotherapy and thoracic irradiation has shown 
improved survival in patients with limited small cell lung cancer compared 
with sequential therapy, and its use in NSCLC is reasonable. In this Phase 
I-II trial we have combined the active agents cisplatin and paclitaxel with 
concurrent TR to 64.8 Gy in patients with unresectable Stage llla and lllb 
NSCLC to assess treatment tolerability, efficacy, and estimate survival. Be- 
tween i/24/94 and 3/20/96 20 patients with Stage Ill NSCLC were entered 
on this trial. One was withdrawn as ineligible, the remaining analysis is 
of all 19 eligible patients. All patients were required to be of ECOG PS 
O-1, have adequate organ function to tolerate radiation and chemother- 
apy, and have no evidence of CNS metastases by enhanced CT or MRI. 
There were 14 men and five women, 2 llla (N2) and 17 Illb, 7 Squamous, 
6 Adenocarcinoma, and 6 Large Cell. Treatment was with Paclitaxel 135 
mg/m* dl and Cisplatin 75 mg/m* d2 four 4 cycles repeated every 28 
days. Radiation was begun day 2 of cycle 1 and treated areas of gross 
disease to 64.8 Gy in 34 fractions over 7 weeks. Elective nodal regions in 
the mediastinum were treated to 50.4 Gy, and supraclavicular nodes were 
not electively treated. Four patients failed to complete protocol treatment 
due to objective progression (1 in SC node), declining PS (2), or refusal (1). 
Objective responses following all therapy were 2 CR, 6 PR, 3 SD, 5 PD, 
3 inevaluable. Major toxicities were hematologic, with Grade 3/4 leukope- 
nia in 16/19 patients and grade 4 esophagitis in 3, Grade 3 in 7. Median 
survival was 11 months for all patients entered. Two patients remain alive 
NED at more than two years from treatment. In this population of patients 
with advanced disease, this regimen was relatively toxic and not clearly 
more effective than sequential chemoradiation or radiotherapy alone, and 
cannot be recommended for routine use. 
15251 Pulmonary function changes in patients with lung 
cancer treated by combined radiation and 
chemotherapy 
N. Barthelemy. L. Bosquee, L. Baugnet, P. Bartsch, J.M. Deneufbourg. 
CHU and Hopital de la Citadel/e 8.4000 Liege and Cen 8.2400 MO/, 
Belgium 
Concomitant radiation and chemotherapy would improve outcome of pa- 
tients with non metastatic advanced lung cancer. However, such com- 
bination might increase the rate of side effects. The present study was 
designed to assess the pulmonary function changes associated with such 
treatments administered with curative intent. So far 11 patients with pri- 
mary lung cancer (stage Ill: A or 9) have been recruited. Chemotherapy 
consisted of cisplatin, ifosfamids and vindesine. For radiation therapy, the 
target volume encompassed the tumor, the ipsilateral hilum, the mediat- 
inum and both supraclavicular fossae. The total dose (40 to 60 Gy) was 
delivered in 2 Gy daily fractions, 5 days a week. Pulmonary function tests 
and dyspnea were assessed before any treatment, when 40 Gy had been 
delivered, during the 2nd, 3rd and 6th month following the completion of 
radiation therapy. Seven patients were afflicted with obstructive lung dis- 
ease (FEVl < 75%) at the time of inclusion. Three patients developped 
transient respiratory insufficiency. On average, there were small and tran- 
sient changes in dyspnea and in FEVl. Diffusion capacity was worsened. 
This worsening was present at 40 Gy and persisted for at least 6 months 
after the end of radiation therapy. We conclude that combined radiation 
and chemotherapy induce moderate pulmonary function changes in most 
patients. This suggests that chemotherapy and external beam radiation 
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can be administered concomitantly without much damage to the lungs. 
Assessment of the value of predictive factors (e.g. pretreatment pulmonary 
function tests, irradiated lung volume, serial determination of TGF-fl blood 
level) in determining which patients are at risk of developping pulmonary 
side effects during such treatments will be presented. 
I 526 Local immunochemotherapy and systemic chemotherapy in early stage (I-II) malignant pleural 
mesothelioma 
A. Chella, A. Ribechini, M. Lucchi, G.F. Menconi, F.M.A. Melfi, P. Dini, 
A. Janni, A. Mussi, C.A. Angeletti. Service of Thoracic Surgery 
Department of Surgew University of P&a, ltaly 
Aim: To date surgery, radiotherapy and chemotherapy have been shown 
to be inadequate in the control of malignant pleural mesothelioma (MPM). 
This phase II study (4/90-10/95) evaluated the ability of a local im- 
munochemotherapy (LICT) and systemic chemotherapy (CT) to prolong the 
time to progression and sutvival in stage I-II MPM (according to Butchard’s 
criteria). 
Methods: 26 elegible patients (pts) were entered into the study. All 
pts underwent thoracoscopy and, after histological diagnosis, ultrasound- 
guided thoracic drainage with 1 OF Percuflex pig-tail catheter (Medi-techa). 
Through it, an intrapleural therapy by epidoxorubicin 30 mg/sqm days 1, 3, 
5 and by a biological response modifier (ERM) (19 pts by 14 mg lyophilized 
Corynebacterium parvum and 7 pts by 18 x 10s UI interleukin-2[r-1121) 
days 7, 9. 11 was administered. Cycles were repeated every 3 weeks until 
pleurodesis or for a max. of 3 courses. After catheter removal, all pts re- 
ceived ifosfamide (I) 3 gr/m* days 1, 2, mesna (80-100% of the I dose), 
vincristine (V) 1.2 mgfm2 day 1 and actinomycin D (A) 1.2 mg/m’ day 1. 
Treatment was repeated, every 3 weeks, for a max. of 6 cycles. The pts, 
who received intrapleural r-112 and achieved an objective response (OR), 
underwent prosecution therapy with low dosage of r-IL2 for 6 mos (3 x 
1OsUI SC, 3 days per week). 
Results: LICT achieved an OR in 24/26 pts with 15 complete responses 
(CRs) (according to Paladine’s criteria). An average of 1.5 courses of LICT 
were necessary with a median drainage period of 29 days. A total of 126 
courses of CT were given (average of 4.6, range 3-6). No treatment-related 
death occurred. The results of CT were 14 OR (4 CR), IO stable disease 
(SD) and 2 progressive disease (PD). Overall median time to progression 
was 12 mos. 18 mos for ORs. Median survival time was 25 mos with 
actuarial l-, 2-, 3-yrs survival rate of 92.0%, 56.1% and 12.4% respectively. 
Today 9 pts are alive and 3 pts are progression free. 
Conclusions: We may conclude that the combination of LICT and CT 
is effective, with acceptable toxicity, in MPM. Further multicenter study with 
a large number of pts is necessary to confirm these high response rates in 
the treatment of MPM. 
III 527 Neoadjuvant multimodal treatment approach for stage Ill non-small cell lung cancer (NSCLC): Results 
of a prospective phase II trial 
M. Thomas, C. Riibe, M. Semik, F. Klinke, M. von Eiff, J. van de Loo. 
Medizinische K/ink und Polk/ink A, Westf8lische W/helms Universitat, 
Albert Schweitzer Str. 33, 48729 Miinster FRG, Germany 
Evaluating a combined neoadjuvant treatment approach in NSCLC- 
patients with surgically proven stage Ill a multicenter phase II trial started 
in 1992: after completion of two cycles of chemotherapy [CT] (Carboplatin 
300 mg/m*; dl/lfosfamid 3 x 1.5 g/m*; dl, 3, 5/Etoposid 3 x 120 mg/m*; 
dl, 3, 5) a 3 week-period of hyperfractionated-accelerated radiotherapy 
[hfRT] (45 Gy; 2 x 1.5 Gy/d) with concurrent Carboplatin (100 mg/m2; dl, 
8, 15)Nindesin (3 mg; dl, 8, 15) followed. 
Up to 9195 54 patients (29 in stage IIIB), median age 57 (range 37-69), 
have been enrolled. Main toxicities turned out in esophagitis (5 x WHO III/IV 
‘) and pneumonitis (5 x WHO III/IV “). 5 treatment related deaths occurred: 
2 due to pneumonitis, 2 because of postoperative bronchopleural fistula 
and one due to postoperative pneumonia. For 37 of 54 (69%) a clinical 
response was achieved. 40/54 (74%) patients went on to surgery with a 
RO-resection - rate of 34/40 (85%). For 23 of 34 patients with RO-resection 
in the surgical specimens no evidence of tumor was found or tumor cells 
amounted less than 10% respectively. 20 of 29 patients in stage IIIB and 
20 of 25 in stage IIIA were operated. Median survival time (MST) for all 
patients is 20.4 mo. (Illa 24.9 mo.; IIIB 17.2 mo.) with a median follow up 
of 32 mo. Compared to inoperable or incomplete resected patients (MST: 
IIIA 11 mo.; IIIB 16.9 mo.) patients with RO-resection lived longer (MST: llla 
35.9 mo.; IIIB 22.2 mo.). With acceptable toxicity this treatment approach 
results in good response- and resection rates, even in stage IIIB patients. 
Compared to conventional treatment MST ist doubled. 
El 528 Phase l/II trial of paclitaxel (Taxol) and radical radiotherapy (XRT) in patients (PTS) with stage Ill 
non-small cell lung cancer (NSCLC) 
P. Kirkbride’, E. Eisenhauer’, K. Gelmon3, B. Fisher’, H. Delude4. 
’ Dept. of Radiation Oncology Princess Margaret Hospital and Univ. of 
Toronto; *National Cancer institute of Canada Clinical Trials Group, 
Queens Univ, Kingston, Ont; 3British Columbia Cancer Agency, 
Vancouver BC; 46ristol-Myers Squibb, Montreal, Quebec, Canada 
The addition of chemotherapy to XRT has been shown to improve survival 
in locally advanced NSCLC. Consequently different chemotherapeutic reg- 
imens in combination with XRT are being evaluated in the treatment of this 
disease. Taxol may be a valuable drug in this situation as, in addition to a 
demonstrated activity in NSCLC, it has been shown the enhance the effect 
of radiation on cell lines in vitro. 
Seventeen patients with stage Ill NSCLC were enrolled onto a phase l/Ii 
trial, to initially determine the maximum tolerated dose (MTD) of paclitaxel 
given by a 3-hour infusion every 2 weeks throughout a 6 week course of 
XRT, 6000 cGy in 30 daily fractions, and then to assess the efficacy of this 
combination. Three patients were entered at each dose level (45, 90. 120 
and 135 mg/m*), except for the 120/m’ dose level which was expanded 
to 9 patients in the phase II part of the study. The dose limiting toxicity 
was neutropenia - 2/3 patients treated at the 135 ms/m2 level experi- 
enced severe granulocytopenia on day 15 which precluded administration 
of scheduled chemotherapy. Esophagitis was only mild, and although pro- 
found lymphopenia was observed, there was no evidence of associated 
opportunistic infections previously described. The overall response rate 
was 58.8% (1 CR, 9 PR, 4 SD and 3 PD). Of the 9 patients treated at the 
MTD, there were 1 CR, PR, 1 SD and 1 PD (response rate = 78%). 
XRT, 6000 cGy in 6 weeks and paclitaxel, 120 mg/mz q 2 weeks is 
a safe combination for patients with NSCLC. Although it demonstrates 
activity in this situation, further investigation is required to define its role in 
the treatment of this disease. 
I 529 Ethical meta-analysis of randomised trials for lung cancer 
M. Zwitter. Institute of Oncology Ljubljana, Slovenia 
In order to promote a more productive debate on the ethics of randomised 
clinical trials (RCTs), I present a survey on the ethical aspects of pub- 
lished RCTs for lung cancer. From the Cancerlit 1993-1995 database, 92 
published randomised trials for lung cancer with a total of 17803 patients 
were identified. The published data were supplemented by a question- 
naire mailed to the authors of these publications. The analysis focused on 
respect of autonomy, non-maleficence, beneficence, and justice as the eth- 
ical principles applicable to society, patients in trials, patients not included 
in RCTs and physicians. 
Results: Full information about the disease and prognosis was offered 
to 60.4% of patients; 55.8% of patients signed a consent form. The ra- 
tio between the recruitment period (mean, 36 months) and time to event 
(mean, 9 months) was greater than 5 in 28 trials; 4 of these trials reported 
a significant overall sutvival advantage. When innovative treatments were 
compared to the standard approach, only a marginal improvement in me- 
dian overall survival (16.7 months vs. 15.7 months) and 2-year survival 
(27.1% vs. 24.2%) was seen, with an accompanying increase of the total 
number of treatment-related deaths (125 vs. 86). 
Ethical Analysis and Conclusion: The benefits to society Include an 
objective evaluation of new treatments; however, in view of only minimal 
therapeutic improvement the strategy of current research for lung cancer 
may need to be re-defined. The principle of autonomy was often violated for 
patients who were inadequately informed about the disease or about RCT. 
In some trials with prolonged recruitment, the principle of non-maleficence 
was not respected since patients continued to be randomised in spite of 
an obvious advantage of one of the treatments. When compared to those 
